Clover Biopharmaceuticals Ltd. (2197) AI Stock Analysis

• Market Cap: HK$389.12M
• Dividend Yield: N/A
• Average Volume (3M): 1.55M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.07
• Revenue Growth: -1.73%
• EPS Growth: -689.53%
• Country: HK
• Employees: 300
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -0.80
• Shares Outstanding: 1,297,062,400
• 10 Day Avg. Volume: 1,299,854
• 30 Day Avg. Volume: 1,553,266
• PEG Ratio: 0.01
• Price to Book (P/B): -3.77
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.40
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 54 Neutral
• Price Target: HK$0.50 ▲(66.67%Upside)

Clover Biopharmaceuticals' financial situation is the most significant factor, heavily weighing down the overall score due to persistent losses, high leverage, and negative cash flows. While technical analysis provides some positive signs, suggesting short-term bullish momentum, valuation concerns remain due to ongoing losses. The absence of positive earnings call data and corporate events further limits the score.

Clover Biopharmaceuticals Ltd. Business Overview & Revenue Model

Company Description

Clover Biopharmaceuticals Ltd. (2197) is a global clinical-stage biotechnology company focused on discovering, developing, and commercializing transformative biologic therapies. The company primarily operates in the biopharmaceutical sector, with a core emphasis on developing vaccines and biologic therapies for infectious diseases and cancer. Clover Biopharmaceuticals leverages its proprietary Trimer-Tag technology platform to create innovative treatments aimed at addressing significant unmet medical needs worldwide.

How the Company Makes Money

Clover Biopharmaceuticals makes money through the development and commercialization of its biologic therapies and vaccines. The company's primary revenue streams include partnerships and collaborations with other pharmaceutical companies, government contracts, and potential sales of its proprietary products upon regulatory approval. Clover's significant partnerships with global health organizations and pharmaceutical firms help fund its research and development efforts while providing opportunities for co-development and commercialization. Additionally, the company may receive milestone payments and royalties from its collaborations, contributing to its earnings as its products progress through clinical trials and towards market approval.

Clover Biopharmaceuticals Ltd. Financial Statement Overview

Summary

Clover Biopharmaceuticals faces significant financial challenges, including persistent losses, negative equity, and negative cash flows. High financial leverage and an inability to generate positive cash flow from operations highlight the company's precarious financial position, which could affect its future operations and growth prospects.

Income Statement

Clover Biopharmaceuticals has consistently reported negative net income, with significant losses in gross profit and EBIT. The revenue growth has been negligible, indicating challenges in generating sales. The negative margins reflect difficulty in controlling costs relative to revenue.

Balance Sheet

The company's balance sheet is highly leveraged, with negative stockholders' equity indicating insolvency risks. The debt-to-equity ratio is not meaningful due to negative equity. Asset base is shrinking, and the negative equity ratio suggests financial instability.

Cash Flow

Operating cash flows have been negative, showing challenges in generating cash from operations. The cash position has decreased over time, and free cash flow is consistently negative, which may hinder future growth and investment capabilities.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	38.42M	39.26M	0.00	0.00	0.00
Gross Profit	-672.94M	24.24M	-475.64M	-66.27M	0.00
EBITDA	-916.54M	-45.07M	-2.39B	-2.23B	-335.04M
Net Income	-903.43M	-138.54M	-2.45B	-6.02B	-915.87M
Balance Sheet
Total Assets	812.74M	2.10B	4.69B	5.35B	1.19B
Cash, Cash Equivalents and Short-Term Investments	427.53M	752.97M	1.64B	2.87B	806.51M
Total Debt	89.64M	334.45M	354.37M	67.92M	22.32M
Total Liabilities	2.45B	2.83B	5.36B	4.13B	2.17B
Stockholders Equity	-1.64B	-732.83M	-668.14M	1.22B	-982.74M
Cash Flow
Free Cash Flow	-290.11M	-737.05M	-1.80B	-998.07M	363.13M
Operating Cash Flow	-288.49M	-727.88M	-1.69B	-917.75M	476.93M
Investing Cash Flow	3.17M	-6.16M	-37.51M	112.12M	-394.12M
Financing Cash Flow	-51.50M	-142.41M	483.14M	3.06B	316.85M

Clover Biopharmaceuticals Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.30
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2197, the sentiment is Positive. The current price of 0.3 is above the 20-day moving average (MA) of 0.27, above the 50-day MA of 0.24, and above the 200-day MA of 0.27, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 66.18 is Neutral, neither overbought nor oversold. The STOCH value of 75.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2197.

Clover Biopharmaceuticals Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	60 Neutral	HK$15.71B	5.67	-7.43%	4.09%	11.60%	-21.06%
2197	54 Neutral	HK$389.12M	―		―	-1.73%	-689.53%
2257	52 Neutral	HK$659.39M	―	-266.90%	―	―	31.23%
6628	47 Neutral	HK$640.84M	―	-32.59%	―	-79.65%	37.50%
2179	46 Neutral	HK$3.81B	―	-69.97%	―	―	3.30%
2142	45 Neutral	HK$7.01B	289.31	2.28%	―	-57.55%	-87.49%
9939	36 Underperform	HK$660.43M	―	-41.20%	―	―	85.23%

Clover Biopharmaceuticals Ltd. Corporate Events

Clover Biopharmaceuticals Announces Board and Committee Changes

Clover Biopharmaceuticals Ltd. announced changes to its board of directors and committee memberships, effective July 1, 2025. Dr. Donna Marie Ambrosino and Mr. Xiang Liao have been appointed as members of the Nomination Committee, reflecting the company’s ongoing efforts to strengthen its governance structure.

Clover Biopharmaceuticals Strengthens Governance with New Nomination Committee

Clover Biopharmaceuticals Ltd. has established a Nomination Committee to oversee director appointments, ensuring diversity and independence within its board. This move is part of the company’s governance strategy to enhance operational efficiency and maintain transparency, potentially strengthening its industry position and stakeholder confidence.

Clover Biopharmaceuticals Announces Unanimous AGM Results and Director Retirement

Clover Biopharmaceuticals Ltd. announced the results of its Annual General Meeting held on June 19, 2025, where all proposed resolutions were passed unanimously. The meeting also marked the retirement of a non-executive director, and the re-election of other directors, along with the appointment of a new auditor, highlighting the company’s stable governance and strategic planning.

Clover Biopharmaceuticals Launches Phase I Trial for New Respiratory Vaccines

Clover Biopharmaceuticals Ltd. has initiated a Phase I clinical trial for its new respiratory combination vaccine candidates, SCB-1022 and SCB-1033, which target RSV, hMPV, and PIV3. This trial follows promising results from a previous study comparing Clover’s RSV PreF vaccine candidate to GSK’s AREXVY, indicating a strong immunogenicity and tolerability profile. The ongoing trial will enroll up to 192 older adults to assess the safety, reactogenicity, and immunogenicity of these new vaccine candidates, potentially strengthening Clover’s position in the vaccine market.

Clover Biopharmaceuticals Ends Distribution Agreement with Adimmune

Clover Biopharmaceuticals Ltd. announced the termination of its exclusive agreement with Adimmune Corporation to distribute AdimFlu-S (QIS) in mainland China, effective June 30, 2025, due to material changes in market conditions. The company believes this termination will not adversely impact its operations and remains focused on advancing its RSV vaccine candidate SCB-1019, which is part of its strategic objectives.

Clover Biopharmaceuticals Faces Arbitration Over $224 Million Claim

Clover Biopharmaceuticals Ltd. announced that it has received an arbitration request from Gavi, seeking repayment of $224 million in advance payment amounts. Clover believes the claim is without merit and intends to defend itself vigorously, while continuing its development of the RSV vaccine candidate SCB-1019.

Clover Biopharmaceuticals Announces 2025 Annual General Meeting Agenda

Clover Biopharmaceuticals Ltd. has announced its upcoming annual general meeting scheduled for June 19, 2025, in Chengdu, China. Key agenda items include the adoption of financial statements for 2024, re-election of directors, and the appointment of auditors. Additionally, the meeting will address resolutions to authorize the board to manage share capital, which may impact the company’s future financial strategies and shareholder value.